AskGene Pharma Received Clearance to Commence Pivotal Phase III Clinical Trial in China for ASKB589
Camarillo, California, October 16, 2023 - AskGene Pharma Inc. announces that the Center for Drug Evaluation (CDE) of the Chinese National Medicinal Product Administration (NMPA) Read More
AskGene Achieves “First in Human” Milestone for ASKG915, A First-in-Class Anti-PD-1/IL-15 Prodrug for the Treatment of Solid Tumors
Camarillo, California, August 21, 2023 - AskGene Pharma Inc. is pleased to announce that the first patient has been dosed at Columbia University Irving Medical Read More
AskGene IGCC 2023 Oral Presentation: Latest Results of ASKB589 Phase I/II Trial
Camarillo, California, June 16, 2023 - AskGene Pharma Inc. today gave an oral presentation at the 15th International Gastric Cancer Congress (IGCC 2023) in Yokohama, Read More
AskGene Will Give an Oral Presentation on the Latest Clinical Results for ASKB589 at IGGC 2023
Camarillo, California, June 2, 2023 - AskGene Pharma Inc. is pleased to announce its participation in the prestigious 15th International Gastric Cancer Congress (IGCC 2023), Read More
AskGene Presents Encouraging Clinical Results on ASKB589 at ASCO-GI 2023
Camarillo, California, January 24, 2023 - AskGene Pharma Inc. presented encouraging clinical results for ASKB589, an anti-CLDN18.2 antibody, at the American Society of Clinical Oncology Read More
AskGene Announces Completion of First Human Dosing of ASKG315, The First IL-15 Prodrug in Clinical Development
Camarillo, California, December 30th, 2022 - AskGene Pharma Inc. is pleased to announce that the first patient completed their first dose (Cycle 1, Day 1) Read More
AskGene Announces Clearance of IND Application by US FDA for ASKG915, A First-in-Class Anti-PD-1-IL-15 Prodrug Fusion Molecule for the Treatment of Patients with Solid Tumors
Camarillo, California, December 30th, 2022 - AskGene Pharma Inc. is pleased to announce that the United States Food and Drug Administration (FDA) has cleared its Read More
AskGene Announces Submission of IND to FDA for ASKG915
Camarillo, California, November 21st, 2022 - AskGene Pharma Inc. is pleased to announce the submission of an Investigational New Drug (IND) application for ASKG915 to Read More
AskGene Presents Latest Results on ASKG315 and ASKG915 at SITC 2022
Camarillo, California, November 15th, 2022 - AskGene presented the pre-clinical results of ASKG315 (IL-15 prodrug) and ASKG915 (PD-1/IL-15 prodrug) at the Society for Immunotherapy of Read More
